Synergistic interaction between paclitaxel and 8-chloro-adenosine 3',5'- monophosphate in human ovarian carcinoma cell lines

Clinical Cancer Research

Volumn 5, Issue 1, 1999, Pages 215-220

  McDaid, Hayley M ^a   Johnston, Patrick G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLOROADENOSINE 3',5' PHOSPHATE; CYCLIC AMP DERIVATIVE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SYNERGISM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0032924968     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Wani, M. C., Taylor, H. L., Wall, M. E., Coggan, P., and McPhail, A. T. Plant antitumor agents: VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 93: 2325-2327, 1971.
2. Rowinsky, E. K., and Donehower, R. C. Paclitaxel (Taxol). N. Engl. J. Med., 332: 1004-1014, 1995.
3. Hortobagyi, G. N., Holmes, F. A., Ibrahim, N., Champlin, R., and Buzdar, A. U. The University of Texas M. D. Anderson Cancer Center experience with paclitaxel in breast cancer. Semin. Oncol., 1 (Suppl. 3): S30-S33, 1997.
4. McGuire, W. P., and Ozols R. F. Chemotherapy of advanced ovarian cancer. Semin. Oncol., 3: 340-348, 1998.
5. Einzig, A. I., Wiernik, P. H., and Sasloff, J. Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J. Clin. Oncol., 10: 1748-1753, 1992.
6. Rao, S., Krauss, N. E., Heerding, J. M., Swindell, C. S., Ringel, I., Orr, G. A., and Horwitz, S. B. 3′-(p-azidobenzamido) taxol photolabels the N-terminal 31 amino-acids of β-tubulin. J. Biol. Chem., 269: 3131-3134, 1994.
7. Rao, S., Orr, G. A., Chaudhary, A. G., Kingston, D. G. I., and Horwitz S. B. Characterization of the Taxol binding site on the microtubule. J. Biol. Chem., 270: 20235-20238, 1995.
8. Schiff, P. B., and Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77: 1561-1565, 1980.
9. Blagosklonny, M. V., Schulte, T., Nguyen, P., Trepel, J., and Nekers, L. M. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involved c-Raf-1 and represents a novel c-Raf-1 signal-transduction pathway. Cancer Res., 56: 1851-1854, 1996.
10. Haldar, S., Chintapalli, J., and Croce, C. N. Taxol induces bcl-2 phosphorylation and death of prostrate cancer cells. Cancer Res., 56: 1253-1255, 1996.
11. Liu, Y., Bhalla, K., Hill, C., and Priest, D. G. Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem. Pharmacol., 48: 1265-1272, 1994.
12. Burkhart, C. A., Berman, J. W., Swindell, C. S., and Horwitz, S. B. Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-α gene expression and cytotoxicity. Cancer Res., 54: 5779-5782, 1994.
13. Saunders, M. P., Salisbury, A. J., Harris, A. L., Long, L., O'Byrne, K. J., Macaulay, V. M., Miki, K., Cho-Chung, Y. S., and Talbot, D. C. Phase I study of the protein kinase A regulator 8-chloro cAMP. Proc. Am. Assoc. Cancer Res., 36: 241, 1995.
14. Tortora, G., Ciardiello, F., Pepe, S., Tagliaferri, P., Ruggiero, A., Bianco, C., Guarrasi, R., Miki, K., and Bianco, A. R. Phase I clinical study with 8-Cl-cAMP and evaluation of immunological effects in cancer patients. Clin. Cancer Res., 1: 377-384, 1995.
15. Cho-Chung, Y. S., and Clair, T. The regulatory subunit of the cAMP-dependent protein kinase as a target for chemotherapy of cancer and other cellular dysfunctional-related diseases. Pharmacol. Ther., 60: 265-288, 1993.
16. Rohlff, C., Clair, T., and Cho-Chung, Y. S. 8-Cl-cAMP induces truncation and down-regulation of the RI α. subunit and up-regulation of the RII β subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells. J. Biol. Chem., 268: 5774-5782, 1993.
17. Ramage, A. D., Langdon, S. P., Ritchie, A. A., Burns, D. J., and Miller, W. R. Growth inhibition by 8-chloro cyclic AMP of human HT29 colorectal and ZR-75-1 breast carcinoma xenografts is associated with selective modulation of protein kinase A isoenzymes. Eur. J. Cancer, 6: 969-973, 1995.
18. Gottesman, M. M., and Pastan, I. Biochemistry of mulitdrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62: 385-427, 1993.
19. Glazer, R. I., and Rohlff, C. Transcriptional regulation of multidrug resistance in breast cancer. Breast Cancer Res. Treat, 31: 263-271, 1994.
20. Scala, S., Budillon, A., Zhan, Z., Cho-Chung, Y. S., Jefferson, J., Tsokos, M., and Bates, S. E. Down-regulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells. J. Clin. Invest., 96: 1026-1034, 1995.
21. Imagawa, M., Chiu, R., and Karin, M. Transcription factor AP-2 mediates induction by two different signal-transduction pathways: protein kinase C and cAMP. Cell, 51: 251-260, 1987.
22. Wilson, A. P. Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary. J. Natl. Cancer Inst. (Bethesda), 72: 513-521, 1984.
23. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
24. Cory, A. H., Owen, T. C., Barltrop, J. A., and Cory, J. G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun., 7: 207-212, 1991.
25. Eisenhauer, E. A., and Vermorken, J. B. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs, 55: 5-30, 1998.
26. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med., 334: 1-6, 1996.
27. Jekunen, A. P., Christen, R. D., Shalinsky, D. R., and Howell, S. B. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br. J. Cancer, 69: 299-306, 1994.
28. Wiernik, P. H., Schwartz, E. L., Strauman, J. J., Dutcher, J. P., Lipton, R. B., and Paietta, E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res., 47: 2486-2493, 1987.
29. Tortora, G., di Isernia, G., Sandomenico, C., Bianco, R., Pomatico, G., Pepe, S., Bianco, A. R., and Ciardiello, F. Synergistic inhibition of growth and induction of apoptosis by 8-Cl-cAMP and paclitaxel or cisplatin in human cancer cells. Cancer Res., 57: 5107-5111, 1997.
30. 6-benzyl-cyclic adenosine 5′-monophosphate on cell cycle kinetics of HL-60 leukemia cells. Cancer Res., 51: 6263-6267, 1991.
31. Blagosklonny, M. V., Giannakakou, P., el-Deiry, W. S., Kingston, D. G., Higgs, P. L., Neckers, L., and Fojo, T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res., 57: 130-135, 1997.
32. Rasouli-Nia, A., Liu, D., Perdue, S., and Britten, R. A. High Raf-1 kinase activity protects human tumor cells against paclitaxel-induced cytotoxicity. Clin. Cancer Res., 4: 1111-1116, 1998.
33. Torres, K., and Horwitz, S. B. Raf-1-dependent and -independent mechanisms of Taxol-mediated cell death. Cancer Res., 58: 3620-3626, 1998.
34. Srivastava, R. K., Srivastava, A. R., Korsmeyer, S. J., Nesterova, M., Cho-Chung, Y. S., and Longo, D. L. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. Cell Biol., 18: 3509-3517, 1998.
35. Gradin, H. M., Larsson, N., Marklund, U., and Gullberg, M. Regulation of microtubule dynamics by extracellular signals: cAMP-dependent protein kinase switches off the activity of oncoprotein 18 in intact cells. J. Cell Biol., 140: 131-141, 1998.
36. Horwitz, S. B., Shen, H. J., He, L., Dittmar, P., Neef, R., Chen, J., and Schubart, U. K. The microtubule-destabilizing activity of metablastin (p19) is controlled by phosphorylation. J. Biol. Chem., 272: 8129-8132, 1997.